Skip to main content

Advertisement

Table 3 Overview of demographic and clinical data as well as inter-group comparisons for the cohorts NMCLRRK2 and CON stratified by gender

From: Inflammatory profile in LRRK2-associated prodromal and clinical PD

  Female
N = 152
Male
N = 96
Female Male
  NMCLRRK2
N = 63
CON
N = 89
NMCLRRK2
N = 52
CON
N = 44
p value
NMCLRRK2
CON
p value
NMCLRRK2
CON
Age
Years
51
23–84
57
18–83
54
27–82
58
28–83
0.087 0.110
UPDRS-III 0
0–13
0
0–9
0
0–15
0
0–8
0.021 0.542
MoCA 28
18–30
27
17–30
27
18–30
27
17–30
0.756 0.809
RBD Questionnaire 1
0–9
1
0–13
2
0–9
1
0–11
0.396 0.943
ESS 6
0–15
6
0–15
5
0–15
6
0–14
0.948 0.399
SCOPA-AUT 8
1–33
7
0–41
7
0–39
6
0–30
0.221 0.729
Regular anti-inflammatory medication
(% of individuals)
3.7 1.2 4.6 0.0 0.561 0.495
  1. Data are presented as median with range. p values reflect results from Mann–Whitney test. The intake of anti-inflammatory medication is given as % of individuals from the respective cohort; statistical analysis was done using chi-square test
  2. NMC LRRK2 non-manifesting LRRK2 mutation carriers, CON healthy control individuals, ESS Epworth Sleepiness Scale, HY Hoehn and Yahr Scale, LEDD levodopa-equivalent daily dosage, MoCA Montreal Cognitive Assessment, RBD REM sleep behavior disorder, UPDRS-III Unified Parkinson’s disease Rating Scale